The most recent trading session ended with Vertex Pharmaceuticals (VRTX) standing at $416.96, reflecting a -1.72% shift from the previouse trading day's closing. The stock's performance was behind the ...

Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...

On Sunday, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced multiple program updates, including: In December, the FDA approved Vertex's Alyftrek (vanzacaftor / tezacaftor ...

Part of that involves looking at the #fundamentals, but half of the disclosure comes from looking at price action.

HHS challenges Vertex Pharmaceuticals' fertility services program, alleging violations of anti-kickback laws linked to its ...

In a report released today, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research ...

ClearBridge Investments, an investment management company, released its “ClearBridge Growth Strategy” fourth quarter 2024 ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by stock analysts at ...

Vertex Pharmaceuticals VRTX has outperformed the market over the past 10 years by 1.52% on an annualized basis producing an ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), retaining the price target of ...

View Vertex Pharmaceuticals Incorporated (VRTX) current and estimated P/E ratio data provided by Seeking Alpha.